Imago BioSciences, Inc. (IMGO)

$16.3

+0.66 (+4.22%)
Rating:
Recommendation:
-
Symbol IMGO
Price $16.3
Beta 0.000
Volume Avg. 0.12M
Market Cap 550.720M
Shares () -
52 Week Range 11.56-30.21
1y Target Est -
DCF Unlevered IMGO DCF ->
DCF Levered IMGO LDCF ->
ROE -27.25% Sell
ROA -28.83% Sell
Operating Margin -
Debt / Equity 4.68% Neutral
P/E -
P/B 2.94 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest IMGO news


Healthcare
Biotechnology
NASDAQ Global Select

Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.